Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

Circulation

Volumn 97, Issue 12, 1998, Pages 1129-1135

  Laufs, Ulrich ^a   La Fata, Vito ^a   Plutzky, Jorge ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Endothelium derived factors; Genes; Lipoproteins

Indexed keywords

CHOLESTEROL; ENDOTHELIUM DERIVED RELAXING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0032584177     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.12.1129     Document Type: Article

References (31)

1. Harrison DG. From isolated vessels to the catheterization laboratory: studies of endothelial function in the coronary circulation of humans. Circulation. 1989;80:703-706.
2. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535-560.
3. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
4. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 1994;89:2176-2182.
5. Radomski MW, Palmer RM, Moncada S. A L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5198-5197.
6. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
7. Tanner FC, Noll G, Boulanger CM, Lüther TF. Oxidized low density lipoprotiens inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012-2020.
8. Cox DA, Cohen ML. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev. 1996;48:3-19
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:- 1383-1389.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
11. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Bocczzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487
12. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
13. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, van Hove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I: endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res. 1986;58:552-564.
14. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68:1027-1034.
15. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319-324.
16. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 1997;95:76-82.
17. Gerson RJ, MacDonald J, Alberts AW, Kornbrust J, Majka JA, Stubbs J. Bokelman DL. Animal safety and toxicology of simvastatin and related hydroxy- methylglutaryl-coenzyme A reductase inhibitors. Am J Med. 1989;87:28-38.
18. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73:3D-11D.
19. Chung BH, Segrest JP, Ras MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1984;128:181-209.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protien measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
21. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1976;15:212-221.
22. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993;214:11-16.
23. Liao JK, Zulueta JJ, Feng-Sheng Y, Peng H, Cote CG, Hassoun PM. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest. 1995;96:2661-2666.
24. Graham FL, Van der Erb AJ. Transformation of rat cells by DNA of human adenovirus 5. Virology. 1973;52:456-457.
25. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. J Biol Chem. 1995;270:15320-15326
26. Rasband W. NIH Image program, v 1.49. Bethesda, Md: National Institutes of Health: 1993.
27. Van Vliet AK, Negre-Aminou P, van Thiel GC, Bolhuis PA, Cohen LH. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative died in cultured myoblasts from human striated muscle. Biochem Pharmacol. 1996;52:1387-1392.
28. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smik RD Jr. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
29. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
30. Falke P, Mattiasson I, Stravenow L, Hood B. Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vivo. Pharmacol Toxicol. 1989;64:173-176.
31. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet. 1994;343:1554-1555.